TP53 and neoplasm: Borderline serous tumours and their type I invasive counterparts are generally low grade, have relatively limited genomic DNA copy number change, have frequent activating RAS pathway mutations, and have substantially lower rates of TP53 mutation compared with type II tumours [20–23].